Avoro Capital Advisors’s Biolase, Inc. BIOL Stock Holding History

Avoro Capital Advisors’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-55	Closed	-$1.39M	–	39
2015 Q1	$1.39M	Sell	55 -8	-13%	-$227K	0.54%	30
2014 Q4	$2.06M	Buy	+63	New	+$1.97M	1.4%	21

Other funds holding BIOL

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boston Partners

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return

Avoro Capital Advisors's BIOL Position: Q2 2015 in Review

Avoro Capital Advisors sold out of Biolase, Inc. (BIOL) in Q2 2015, closing a stake of 55 shares — an estimated $1.39M sold.

Avoro Capital Advisors first reported a position in BIOL in Q4 2014 and held it in 2 quarters. The position peaked at $2.06M in Q4 2014. 34 funds tracked by Wall St. Rank hold BIOL as of Q2 2015.

Avoro Capital Advisors reported no remaining Biolase, Inc. position as of Q2 2015 after selling out during the quarter.
Avoro Capital Advisors sold 55 Biolase, Inc. shares in Q2 2015, an estimated $1.39M.
Avoro Capital Advisors first reported a position in Biolase, Inc. in Q4 2014 and held it in 2 quarters.
Avoro Capital Advisors's Biolase, Inc. position peaked at $2.06M in Q4 2014.
34 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2015.

Based on Avoro Capital Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.